Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual modeof action: serotonin reuptake inhibition and 5-HT1A receptor antagonism

Citation
Am. Oficialdegui et al., Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual modeof action: serotonin reuptake inhibition and 5-HT1A receptor antagonism, FARMACO, 55(5), 2000, pp. 345-353
Citations number
42
Categorie Soggetti
Pharmacology & Toxicology
Journal title
FARMACO
ISSN journal
0014827X → ACNP
Volume
55
Issue
5
Year of publication
2000
Pages
345 - 353
Database
ISI
SICI code
0014-827X(200005)55:5<345:DSABEO>2.0.ZU;2-H
Abstract
It has been suggested that the combination of a selective serotonin reuptak e inhibitor (SSRI) and a 5-HT1A receptor antagonist may facilitate the onse t of the SSRIs antidepressant action. Accordingly, we describe the synthesi s of a series of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives w ith structural modifications performed in Ar-1, Ar-2 and Z (Z is different functional groups) to obtain the sought dual activity. Compounds were evalu ated for in vitro affinity at 5-HT1A receptors and 5-HT transporter. The an tidepressant-like activity of derivatives with the higher affinity was asse ssed initially using the forced swimming test (FST). Compound 1 -(2,4-dimet hylphenyl)-3-[(2-methoxyphenyl)piperazin-1-il]-1-propanone (III.1.a) showed the best antidepressant-like activity which was further confirmed in the l earned helplessness test. (C) 2000 Elsevier Science S.A. All rights reserve d.